Pacira BioSciences (PCRX) Net Cash Flow Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | -1,020.00% |
| 10 | Pacira BioSciences | 1.07 Bn | 864.71 Mn | 140.96 Mn | -308.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -308.85% |
| Dec 31, 2025 | -63.10% |
| Sep 30, 2025 | -13,965.07% |
| Jun 30, 2025 | -73.54% |
| Mar 31, 2025 | -77.77% |
| Dec 31, 2024 | -43.13% |
| Sep 30, 2024 | -108.84% |
| Jun 30, 2024 | 22.89% |
| Mar 31, 2024 | 144.83% |
| Dec 31, 2023 | 1,125.15% |
| Sep 30, 2023 | 197.40% |
| Jun 30, 2023 | 148.97% |
| Mar 31, 2023 | 80.88% |
| Dec 31, 2022 | -101.17% |
| Sep 30, 2022 | -144.71% |
| Jun 30, 2022 | -367.92% |
| Mar 31, 2022 | -978.92% |
| Dec 31, 2021 | 1,885.67% |
| Sep 30, 2021 | -39.47% |
| Jun 30, 2021 | 63.06% |